Consensus Alvotech NYSE

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

Market Closed - NYSE 16:00:00 2026-09-03 EDT			5-day change	1st Jan Change
5.380 ^USD	+0.75%		+8.76%	-42.64%

08-31	Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80	MT
08-31	Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

91c3e24b7cb.qmFqaTEK-2-fMIgr8mFhYwsnSnx11m-VGQLgeVwdsPM.6TdZHWtAkALqBP9fv0wMC2VRHko-j1bncGCjNy12w8bYWQclYFK5ItBbyQ~cd9db50d9aff1ec01e6c9411f5f1b20d

Analysts' recommendations: Alvotech

08-24	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
08-24	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
03-24	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
03-24	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
12-22	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
11-18	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
11-04	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
11-03	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
11-03	Top Premarket Decliners	MT
11-03	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
11-02	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
25-10-14	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
25-10-14	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
25-09-23	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
25-09-23	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
25-07-21	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
25-07-18	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
24-07-25	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24-05-24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
24-03-22	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT
24-01-29	Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	MT
23-10-20	Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	MT
23-09-21	Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+17.44%
	REVOLUTION MEDICINES, INC.					+18.9%
	IQVIA HOLDINGS INC.					+4.71%
	BEONE MEDICINES AG					+19.45%
	CELLTRION, INC.					+42.8%
	ASCENDIS PHARMA A/S					+17.43%
	MEDPACE HOLDINGS, INC.					-1.89%
	EUROFINS SCIENTIFIC SE					-0.35%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.69%
	Average					+12.76%
	Weighted average by Cap.					+15.82%